Penserra Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-22
Closed -$12K – 1089
2022
Q2
$12K Buy
22
+7
+47% +$5.98K ﹤0.01% 1206
2022
Q1
$15K Buy
15
+6
+67% +$8.11K ﹤0.01% 1327
2021
Q4
$21K Buy
+9
New +$25.3K ﹤0.01% 1232

Other funds holding JSPR

Penserra Capital Management's JSPR Position: Q3 2022 in Review

Penserra Capital Management sold out of Jasper Therapeutics (JSPR) in Q3 2022, closing a stake of 22 shares — an estimated $12K sold.

Penserra Capital Management first reported a position in JSPR in Q4 2021 and held it in 3 quarters. The position peaked at $21K in Q4 2021. 22 funds tracked by Wall St. Rank hold JSPR as of Q3 2022.

  • Penserra Capital Management reported no remaining Jasper Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 22 Jasper Therapeutics shares in Q3 2022, an estimated $12K.
  • Penserra Capital Management first reported a position in Jasper Therapeutics in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's Jasper Therapeutics position peaked at $21K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.